How mutant IDH affects bile duct cancer
Functions of mutant IDH in cholangiocarcinoma
This study is looking at how a specific mutation in a gene called IDH1 affects bile duct cancer and helps cancer cells hide from the immune system, with the hope of finding better ways to treat this cancer by combining current therapies with new immune treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10932410 on NIH RePORTER |
What this research studies
This research investigates the role of mutant isocitrate dehydrogenase 1 (IDH1) in cholangiocarcinoma, a severe form of bile duct cancer. It focuses on how these mutations produce a substance that alters cancer cell behavior, allowing them to evade the immune system. By using advanced mouse models and patient samples, the research aims to understand the mechanisms behind this immune evasion and how it can be reversed to improve treatment outcomes. The ultimate goal is to enhance the effectiveness of existing therapies by combining them with immune checkpoint inhibitors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with cholangiocarcinoma, particularly those with IDH1 mutations.
Not a fit: Patients without cholangiocarcinoma or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for cholangiocarcinoma by improving the immune response against the cancer.
How similar studies have performed: Other research has shown promising results in targeting similar metabolic pathways in cancer, indicating potential for success in this approach.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: El-Bardeesy, Nabeel — Massachusetts General Hospital
- Study coordinator: El-Bardeesy, Nabeel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.